NexImmune Announces Formation of Scientific Advisory Board
GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc.(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Scientific Advisory Board (SAB).
- GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc.(Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Scientific Advisory Board (SAB).
- Long Professor of Immunobiology and of Medicine (Endocrinology), Yale University; Deputy Director, Yale Center for Clinical Investigation; Co-Director, Yale Diabetes Center.
- Jonathan Schneck, MD, PhD, Professor, Department of Pathology, Medicine and Oncology, The Johns Hopkins University School of Medicine; Director, The Johns Hopkins Translational ImmunoEngineering Center; Co-founder NexImmune.
- The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response.